These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 17011383)
1. Darifenacin: Pharmacology and clinical usage. Steers WD Urol Clin North Am; 2006 Nov; 33(4):475-82, viii. PubMed ID: 17011383 [TBL] [Abstract][Full Text] [Related]
2. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Foote J; Glavind K; Kralidis G; Wyndaele JJ Eur Urol; 2005 Sep; 48(3):471-7. PubMed ID: 15990219 [TBL] [Abstract][Full Text] [Related]
3. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB. Zinner N; Susset J; Gittelman M; Arguinzoniz M; Rekeda L; Haab F Int J Clin Pract; 2006 Jan; 60(1):119-26. PubMed ID: 16409440 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. Kay GG; Wesnes KA BJU Int; 2005 Nov; 96(7):1055-62. PubMed ID: 16225528 [TBL] [Abstract][Full Text] [Related]
6. Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Chapple C; DuBeau C; Ebinger U; Rekeda L; Viegas A Curr Med Res Opin; 2007 Oct; 23(10):2347-58. PubMed ID: 17706004 [TBL] [Abstract][Full Text] [Related]
7. Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study. Dwyer P; Kelleher C; Young J; Haab F; Lheritier K; Ariely R; Ebinger U Neurourol Urodyn; 2008; 27(6):540-7. PubMed ID: 18663723 [TBL] [Abstract][Full Text] [Related]
8. Darifenacin in the treatment of overactive bladder. Parsons M; Robinson D; Cardozo L Int J Clin Pract; 2005 Jul; 59(7):831-8. PubMed ID: 15963212 [TBL] [Abstract][Full Text] [Related]
9. Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Chapple CR Expert Opin Investig Drugs; 2004 Nov; 13(11):1493-500. PubMed ID: 15500396 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. Zinner N; Tuttle J; Marks L World J Urol; 2005 Sep; 23(4):248-52. PubMed ID: 16096831 [TBL] [Abstract][Full Text] [Related]
11. Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Zinner N Expert Opin Pharmacother; 2007 Mar; 8(4):511-23. PubMed ID: 17309345 [TBL] [Abstract][Full Text] [Related]
12. Increased warning time with darifenacin: a new concept in the management of urinary urgency. Cardozo L; Dixon A J Urol; 2005 Apr; 173(4):1214-8. PubMed ID: 15758755 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of health-related quality of life outcomes with darifenacin. Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056 [TBL] [Abstract][Full Text] [Related]
15. Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Chapple CR; Abrams P Eur Urol; 2005 Jul; 48(1):102-9. PubMed ID: 15936869 [TBL] [Abstract][Full Text] [Related]
16. Muscarinic receptors in the bladder: from basic research to therapeutics. Hegde SS Br J Pharmacol; 2006 Feb; 147 Suppl 2(Suppl 2):S80-7. PubMed ID: 16465186 [TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. Haab F; Corcos J; Siami P; Glavind K; Dwyer P; Steel M; Kawakami F; Lheritier K; Steers WD BJU Int; 2006 Nov; 98(5):1025-32. PubMed ID: 16879437 [TBL] [Abstract][Full Text] [Related]
18. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q). Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182 [TBL] [Abstract][Full Text] [Related]
19. Solifenacin in the management of the overactive bladder syndrome. Robinson D; Cardozo L Int J Clin Pract; 2005 Oct; 59(10):1229-36. PubMed ID: 16178992 [TBL] [Abstract][Full Text] [Related]
20. Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Hill S; Khullar V; Wyndaele JJ; Lheritier K; Int Urogynecol J Pelvic Floor Dysfunct; 2006 May; 17(3):239-47. PubMed ID: 15999217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]